Arcutis Biotherapeutics, Inc., a biopharmaceutical company based in Westlake Village, United States, has been making significant strides in the health care sector. Specializing in the development of treatments for immune-mediated diseases and conditions, Arcutis is dedicated to addressing unmet medical needs. The company is publicly traded on the Nasdaq under the currency of USD.
As of October 13, 2026, Arcutis Biotherapeutics reported a close price of $26.41. Over the past year, the company’s stock has experienced fluctuations, reaching a 52-week high of $31.77 on December 7, 2025, and a 52-week low of $19.295 on May 18, 2026. These figures reflect the dynamic nature of the biopharmaceutical market and the company’s ongoing efforts to innovate and expand its therapeutic offerings.
Arcutis Biotherapeutics boasts a market capitalization of $3.28 billion, underscoring its significant presence in the biopharmaceutical industry. The company’s financial metrics, including a price-to-earnings ratio of 121.96, highlight its growth potential and the market’s expectations for its future performance.
The company’s focus on immune-mediated diseases positions it at the forefront of addressing critical health challenges. By leveraging cutting-edge research and development, Arcutis aims to deliver innovative solutions that can transform patient care. The company’s commitment to meeting the medical sector’s requirements is evident in its strategic initiatives and partnerships.
For those interested in learning more about Arcutis Biotherapeutics’ activities and offerings, further information is available on their official website at www.arcutis.com . The company continues to pursue its mission of developing groundbreaking therapies, contributing to the advancement of health care and improving patient outcomes.
